Trial Profile
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC [doxorubicin + cyclophosphamide] Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel; Trastuzumab
- Indications Adenocarcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 07 Jun 2022 Results of a pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 studies assessed the the association of intrinsic subtypes and gene expression signatures with pathologic complete response and event-free survival presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 05 May 2020 Results (n=130) of biomarker analyses assessing prognostic utility of ERBB2, ESR1 and other genomic markers were published in the Clinical Cancer Research
- 04 Jun 2019 Status changed to completed as per results presented at the 55th Annual Meeting of the American Society of Clinical Oncology